PD-1 and PD-L1 inhibitors are a group of immune checkpoint inhibitors (ICIs) used in the treatment of multiple types of cancer; these include atezolizumab, durvalumab, pembrolizumab, and nivolumab. The gene discussed is PDCD1; the disease is cancer.